CA2253811C - Taste masked liquid suspensions - Google Patents
Taste masked liquid suspensions Download PDFInfo
- Publication number
- CA2253811C CA2253811C CA002253811A CA2253811A CA2253811C CA 2253811 C CA2253811 C CA 2253811C CA 002253811 A CA002253811 A CA 002253811A CA 2253811 A CA2253811 A CA 2253811A CA 2253811 C CA2253811 C CA 2253811C
- Authority
- CA
- Canada
- Prior art keywords
- active ingredient
- pharmaceutically active
- pharmaceutical composition
- polymer
- taste masked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000019640 taste Nutrition 0.000 title claims abstract description 68
- 239000006194 liquid suspension Substances 0.000 title description 3
- 229920000642 polymer Polymers 0.000 claims abstract description 86
- 239000004480 active ingredient Substances 0.000 claims abstract description 74
- 239000000725 suspension Substances 0.000 claims abstract description 46
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 27
- 125000001453 quaternary ammonium group Chemical group 0.000 claims abstract description 16
- 230000001419 dependent effect Effects 0.000 claims abstract description 10
- 239000003094 microcapsule Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 23
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 21
- 229960005224 roxithromycin Drugs 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 210000000214 mouth Anatomy 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- 238000004090 dissolution Methods 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 239000006172 buffering agent Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001534 risperidone Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
- -1 alkaline earth metal cations Chemical class 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical group CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 229960001193 diclofenac sodium Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- MHNFDKSVERZGHK-UHFFFAOYSA-N n,n-diethylethanamine;2-methylprop-2-enoic acid Chemical compound CC(=C)C([O-])=O.CC[NH+](CC)CC MHNFDKSVERZGHK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 150000003892 tartrate salts Chemical class 0.000 claims description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims description 2
- 229960001128 triprolidine Drugs 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000576 coating method Methods 0.000 abstract description 10
- 239000011248 coating agent Substances 0.000 abstract description 9
- 230000000873 masking effect Effects 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229940069428 antacid Drugs 0.000 description 5
- 239000003159 antacid agent Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 5
- 229960004144 josamycin Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 230000001458 anti-acid effect Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 3
- 229920005597 polymer membrane Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KYAPHMSJPGQOSY-OTHJGQCISA-N (3r,4s,5s,6r,7r,9r,10e,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-(2-methoxyethoxymethoxy)-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9 Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OCOCCOC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYAPHMSJPGQOSY-OTHJGQCISA-N 0.000 description 1
- UUGXDEDGRPYWHG-UHFFFAOYSA-N (dimethylamino)methyl 2-methylprop-2-enoate Chemical compound CN(C)COC(=O)C(C)=C UUGXDEDGRPYWHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN9697A AUPN969796A0 (en) | 1996-05-07 | 1996-05-07 | Taste masked liquid suspensions |
| AUPN9697 | 1996-05-07 | ||
| PCT/AU1997/000279 WO1997041839A1 (en) | 1996-05-07 | 1997-05-07 | Taste masked liquid suspensions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2253811A1 CA2253811A1 (en) | 1997-11-13 |
| CA2253811C true CA2253811C (en) | 2006-10-24 |
Family
ID=3794010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002253811A Expired - Fee Related CA2253811C (en) | 1996-05-07 | 1997-05-07 | Taste masked liquid suspensions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6197348B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP0921789B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4624498B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE258432T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AUPN969796A0 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2253811C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69727386T2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0921789T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2215223T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT921789E (cg-RX-API-DMAC10.html) |
| WO (1) | WO1997041839A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2754177B1 (fr) * | 1996-10-07 | 1999-08-06 | Sanofi Sa | Microspheres pharmaceutiques d'acide valproique pour administration orale |
| DE19809719A1 (de) | 1998-03-06 | 1999-09-09 | Roehm Gmbh | Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen |
| DE19845358A1 (de) * | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe |
| ATE424191T1 (de) * | 1999-02-04 | 2009-03-15 | Abbott Lab | Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| HK1049622A1 (en) * | 1999-12-28 | 2003-05-23 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| CA2401571A1 (en) * | 2000-02-29 | 2001-09-07 | Ilya Avrutov | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
| FR2826274B1 (fr) * | 2001-06-21 | 2003-09-26 | Aventis Pharma Sa | Formulation pharmaceutique au gout masque et son procede de preparation |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| BR0308343A (pt) * | 2002-03-12 | 2006-06-06 | Bristol Myers Squibb Co | composições farmacêuticas na forma de pó, método para preparar uma suspensão oral de uma droga, método para mascarar o sabor amargo ou outro sabor de uma droga e suspensão oral de des-quinolona |
| US6930119B2 (en) * | 2002-07-17 | 2005-08-16 | Reliant Pharmaceuticals, Inc. | Liquid pharmaceutical composition |
| WO2004026283A1 (en) * | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sequestering subunit and related compositions and metohds |
| US20040091544A1 (en) * | 2002-11-08 | 2004-05-13 | Ruff Michael D. | Coated dibasic calcium phosphate |
| US20040170686A1 (en) * | 2003-01-31 | 2004-09-02 | Fredrickson Jennifer K. | Suspension vehicle for coated drug particles |
| US20040186180A1 (en) | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
| US20040191326A1 (en) * | 2003-03-31 | 2004-09-30 | Reo Joseph P. | Taste-masking vehicle for coated oxazolidinone particles |
| US7520489B2 (en) * | 2003-06-17 | 2009-04-21 | Filtertek Inc. | Fluid handling device and method of making same |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| US20050137262A1 (en) * | 2003-12-22 | 2005-06-23 | Hu Patrick C. | Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| EP1763337A2 (en) * | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
| JP2007517050A (ja) * | 2003-12-31 | 2007-06-28 | アクタビス グループ フルータフェーラグ | アトモキセチン製剤 |
| US20050163842A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone and metformin formulations |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
| US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
| US20050163843A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
| WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
| AU2005278894A1 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
| GB2419094A (en) * | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
| US7378109B2 (en) * | 2004-12-23 | 2008-05-27 | Council Of Scientific And Industrial Research | Pharmaceutical composition for improving palatability of drugs and process for preparation thereof |
| CA2598668A1 (en) * | 2005-02-25 | 2006-09-08 | Mutual Pharmaceutical Company, Inc. | Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents |
| BRPI0611272A2 (pt) * | 2005-05-03 | 2011-11-16 | Mutual Pharmaceutical Co | formulações de quinina |
| CN1883456B (zh) * | 2005-06-20 | 2010-12-15 | 常州市第四制药厂有限公司 | 掩味药物颗粒及其制备方法和用途 |
| JP2007031407A (ja) * | 2005-07-29 | 2007-02-08 | Shin Etsu Chem Co Ltd | 低置換度セルロースエーテル含有コーティング用組成物及び不快な味が隠蔽されたフィルムコーティング製剤 |
| US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
| US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| AU2007227614B2 (en) * | 2006-03-16 | 2011-01-06 | Gsk Consumer Healthcare Sarl | Solid dosage form containing a taste masked active agent |
| JP4892264B2 (ja) * | 2006-03-30 | 2012-03-07 | 高田製薬株式会社 | リスペリドン水性液剤 |
| KR20140079441A (ko) * | 2006-06-19 | 2014-06-26 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| US7915247B1 (en) | 2006-08-21 | 2011-03-29 | Mutual Pharmaceutical Company, Inc. | Methods of use of fenofibric acid |
| CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
| US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| US20100062073A1 (en) * | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| WO2008081774A1 (ja) * | 2006-12-26 | 2008-07-10 | Shionogi & Co., Ltd. | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
| JP4941977B2 (ja) * | 2007-04-11 | 2012-05-30 | 大蔵製薬株式会社 | ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物 |
| WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
| WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
| US8309129B2 (en) * | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
| WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
| US8974827B2 (en) * | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| EP2178518A2 (en) * | 2007-07-13 | 2010-04-28 | Bend Research, Inc | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| EP2240162A4 (en) * | 2007-12-06 | 2013-10-09 | Bend Res Inc | NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER |
| AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| KR101294648B1 (ko) | 2009-03-27 | 2013-08-09 | 도레이 카부시키가이샤 | 피복 고형제제 |
| US20110150986A1 (en) * | 2009-12-18 | 2011-06-23 | Kristin Arnold | Quinine formulations, method of making, and metho of use thereof |
| JP5819329B2 (ja) * | 2010-03-09 | 2015-11-24 | アルカーメス ファーマ アイルランド リミテッド | アルコール耐性腸溶性医薬組成物 |
| WO2013156163A1 (en) | 2012-04-19 | 2013-10-24 | Glatt Ag | Taste-masked pharmaceutical compositions containing diclofenac |
| JP2015537029A (ja) | 2012-11-14 | 2015-12-24 | ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ | 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物 |
| US11202741B2 (en) * | 2015-09-30 | 2021-12-21 | Amorepacific Corporation | Self-restorable core-shell capsule |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| WO2020011938A1 (en) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
| CN113181133A (zh) * | 2021-04-25 | 2021-07-30 | 海南通用三洋药业有限公司 | 一种罗红霉素胶囊的制备方法 |
| CN116687843A (zh) * | 2022-12-16 | 2023-09-05 | 中国人民解放军军事科学院军事医学研究院 | 一种高稳定性的布瓦西坦溶液及其制备方法和其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5286489A (en) * | 1985-08-26 | 1994-02-15 | The Procter & Gamble Company | Taste masking compositions |
| JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
| JPS63218247A (ja) * | 1987-03-06 | 1988-09-12 | Yoshiaki Kawashima | 高機能懸濁液 |
| ES2054089T3 (es) * | 1988-11-10 | 1994-08-01 | Ciba Geigy Ag | Formulaciones orales liquidas. |
| US5084278A (en) * | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
| IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| AU8219191A (en) * | 1990-06-14 | 1992-01-07 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
| GB9015822D0 (en) * | 1990-07-18 | 1990-09-05 | Beecham Group Plc | Compositions |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
| JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| CA2137265C (en) * | 1992-06-04 | 2003-10-28 | Sanjay Bhardwaj | Palatable pharmaceutical compositions |
| WO1994025006A1 (en) | 1993-04-26 | 1994-11-10 | Affinity Biotech, Inc. | Taste-masking pharmaceutical compositions and methods for making the same |
| ZA945944B (en) | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
-
1996
- 1996-05-07 AU AUPN9697A patent/AUPN969796A0/en not_active Abandoned
-
1997
- 1997-05-07 DK DK97917939T patent/DK0921789T3/da active
- 1997-05-07 EP EP97917939A patent/EP0921789B1/en not_active Expired - Lifetime
- 1997-05-07 ES ES97917939T patent/ES2215223T3/es not_active Expired - Lifetime
- 1997-05-07 CA CA002253811A patent/CA2253811C/en not_active Expired - Fee Related
- 1997-05-07 DE DE69727386T patent/DE69727386T2/de not_active Expired - Lifetime
- 1997-05-07 US US09/180,354 patent/US6197348B1/en not_active Expired - Fee Related
- 1997-05-07 AT AT97917939T patent/ATE258432T1/de active
- 1997-05-07 WO PCT/AU1997/000279 patent/WO1997041839A1/en not_active Ceased
- 1997-05-07 PT PT97917939T patent/PT921789E/pt unknown
- 1997-05-07 JP JP53935397A patent/JP4624498B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6197348B1 (en) | 2001-03-06 |
| JP2000509399A (ja) | 2000-07-25 |
| DK0921789T3 (da) | 2004-06-01 |
| EP0921789B1 (en) | 2004-01-28 |
| PT921789E (pt) | 2004-06-30 |
| JP4624498B2 (ja) | 2011-02-02 |
| DE69727386T2 (de) | 2004-11-11 |
| CA2253811A1 (en) | 1997-11-13 |
| ES2215223T3 (es) | 2004-10-01 |
| EP0921789A4 (en) | 2002-03-13 |
| WO1997041839A1 (en) | 1997-11-13 |
| DE69727386D1 (de) | 2004-03-04 |
| ATE258432T1 (de) | 2004-02-15 |
| AUPN969796A0 (en) | 1996-05-30 |
| EP0921789A1 (en) | 1999-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2253811C (en) | Taste masked liquid suspensions | |
| US10568832B2 (en) | Taste-masked pharmaceutical compositions | |
| CA2169376C (en) | Procedure for encapsulating nsaids | |
| US4800087A (en) | Taste-masked pharmaceutical compositions | |
| US5084278A (en) | Taste-masked pharmaceutical compositions | |
| HU219592B (hu) | Hatóanyagként ciprofloxacint tartalmazó, ízmaszkírozott gyógyászati készítmények és eljárás előállításukra | |
| US20050136114A1 (en) | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer | |
| US20110212182A1 (en) | Masked taste pharmaceutical granules/granulates | |
| CA2304630A1 (en) | Taste masked formulations | |
| IE873306L (en) | Liquid dosage form for oral administration | |
| JP2003531163A (ja) | 味をマスクするコーチング組成物 | |
| HRP20020924A2 (en) | Pharmaceutical composition | |
| US6565877B1 (en) | Taste masked compositions | |
| AU2003292509B2 (en) | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer | |
| US20020142038A1 (en) | Process for preparing solid dosage forms for unpalatable pharmaceuticals | |
| EP1194124B1 (en) | Taste masked compositions | |
| IE902829A1 (en) | Microencapsulated taste-masked water-insoluble nsaid drug¹materials | |
| AU719137B2 (en) | Taste masked liquid suspensions | |
| HUP0200711A2 (hu) | Iható gyógyszerészeti szuszpenzió | |
| CA2802142C (en) | Ciprofloxacin dry syrup composition | |
| CA2008005A1 (en) | Microencapsulated taste-masked water-insoluble nsaid drug materials | |
| MX2007004260A (en) | Taste-masking pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140507 |